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Stroke is the leading cause of morbidity and mortality worldwide. About 87% of stroke
cases are ischemic, which disrupt the physiological activity of the brain, thus leading
to a series of complex pathophysiological events. Despite decades of research on
neuroprotectants to probe for suitable therapies against ischemic stroke, no successful
results have been obtained, and new alternative approaches are urgently required
in order to combat this pathological torment. To address these problems, drug
repositioning/reprofiling is explored extensively. Drug repurposing aims to identify new
uses for already established drugs, and this makes it an attractive commercial strategy.
Nuclear factor-kappa beta (NF-κB) is reported to be involved in many physiological
and pathological conditions, such as neurodegeneration, neuroinflammation, and
ischemia/reperfusion (I/R) injury. In this study, we examined the neuroprotective effects
of atorvastatin, cephalexin, and mycophenolate against the NF-κB in ischemic stroke,
as compared to the standard NF-κB inhibitor caeffic acid phenethyl ester (CAPE). An
in-silico docking analysis was performed and their potential neuroprotective activities in
the in vivo transient middle cerebral artery occlusion (t-MCAO) rat model was examined.
The percent (%) infarct area and 28-point composite neuro score were examined, and an
immunohistochemical analysis (IHC) and enzyme-linked immunosorbent assay (ELISA)
were further performed to validate the neuroprotective role of these compounds in stroke
as well as their potential as antioxidants. Our results demonstrated that these novels
NF-κB inhibitors could attenuate ischemic stroke-induced neuronal toxicity by targeting
NF-κB, a potential therapeutic approach in ischemic stroke.
Keywords: reprofiling, MCAO stroke, p-NF-κB, atorvastatin, cephalexin, mycophenolate, caeffic acid
phenethyl ester
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inhibitory subunit of κB (IκB), a pro-inflammatory mediator.
Oxidative stress, cytokines, carcinogens, viruses, and bacterial
toxins induce the transition of NF-κB from the inactive to the
active state. This is due to breakage of the NF-κB/IκB complex
and further proteasomal degradation of cytosolic IκB set free NFκB for nuclear translocation. In the nucleus, NF-κB regulates
transcription of different inflammatory and apoptotic genes
(Stephenson et al., 2000). Residues of NF-κB-p50 involved in
interactions with DNA are: tyrosine-36, arginine-54, arginine-56,
tyrosine-57, cysteine-59, glutamic acid-60, histidine-64, lysine144, lysine-145, lysine-272, glutamine-274, and arginine-305
(Chen et al., 1998; Berkowitz et al., 2002).
Caffeic acid phenethyl ester (CAPE) is a potential NF-κB
inhibitor, as demonstrated by several studies (Russo et al., 2002;
Li et al., 2017). CAPE is reported to have anti-inflammatory,
antioxidant, immunomodulatory, and anticancer properties
(Murtaza et al., 2014). Furthermore, CAPE exhibited protective
effects in a rat MCAO model, and it also attenuated infarction
and neuroinflammation by the NF-κB-dependent pathway
(Khan et al., 2007). In the present study, we docked CAPE with
NF-κB, and the subsequent interactions were taken as a reference
for FDA drug-NF-κB complex. Atorvastatin, mycophenolate,
and cephalexin were selected from about 580 drugs compare
to the referenced CAPE-NF-κB complex. Moreover, in silico
molecular docking results were further validated by in vivo
experiments. Taken together all these, our results suggested that
drug repurposing could be a safe and time and cost-effective
option for drug development in ischemic stroke.

INTRODUCTION
Ischemic stroke is characterized by a decrease in cerebral
blood flow (CBF) and deprivation of both glucose and
oxygen, which are required to maintain the metabolic demands
of the brain (Siniscalchi et al., 2014). Reliable for infarct
production, focal cerebral ischemia models, such as transient
or permanent middle cerebral artery occlusion (MCAO),
closely resemble human ischemic stroke (Fluri et al., 2015),
and these are majorly probed for ischemic pathophysiological
processes or related neuroprotective strategies (Shah et al.,
2019c). Ischemia-induced brain detriment may be partially
recovered if appropriate treatment is given within a certain
time frame, i.e., approximately 3–4.5 h. Thrombolytics, such
as tissue-type plasminogen activator (t-PA), and embolectomy,
such as craniectomy, are the approved treatments for ischemic
stroke (Drieu et al., 2018). However, t-PA application is limited
by its side effects and short therapeutic window (Khan et al.,
2007). According to the stroke treatment academy industry
roundtable (STAIR) guidelines, stroke treatment should be
initiated within 3–4.5 h after symptom onset. Moreover, the
effectiveness of t-PA reduces and the danger of complications
increases even within this time frame (Yperzeele et al., 2014).
The most notable complication with t-PA is hemorrhagic
stroke-like intracranial hemorrhage, which further compromises
the clinical scope of t-PA in ischemic stroke (Liu et al., 2004).
Furthermore, t-PA administration after this time window may
cause neurovascular damage, such as neuroinflammation and
oxidative stress, which facilitate leukocyte infiltration, increase
reactive oxygen species (ROS), and cause an intracellular calcium
surge (Zhang et al., 2005).
Successful management of stroke remains a major challenge
in the clinical setup. Pre-clinical studies from the last decade
have identified hundreds of neuroprotective agents, but not
a single moiety successfully passed the clinical trials. A long
list of perplex factors, such as complex brain structure, longer
time window, diverse or different outcome strategies, no precise
target, heterogeneity of stroke, and a lack of optimal duration
of drug administration, are among the major variants of drug
failure in clinical trials (Cheng et al., 2004). As a result, drug
development is severely hampered due to high expenditure,
which rose from US$ 4 billion in 1975 to US$ 40 billion in 2009
(Schuhmacher et al., 2016). To address these problems, drug
repositioning, also known as reprofiling, is increasingly explored
(Padhy and Gupta, 2011) as an alternative attractive strategy.
Nuclear factor-kappa beta (NF-κB) is ubiquitously expressed
in the cytoplasm and executes various functions, ranging from
cell proliferation and cell differentiation to cell death (Manavalan
et al., 2010). Previous studies demonstrated the involvement
of NF-κB in Alzheimer’s disease (AD), Parkinson’s disease
(PD), and ischemic stroke (Sivandzade et al., 2019), while
NF-κB inhibition played a key role in reversing these disease
pathologies. NF-κB is composed of several subunits, such as
p65 (RelA), RelB, c-Rel, p105/p50 (NF-κB1), and p100/p52 (NFκB2), which, upon activation, assemble to form homo- or heterodimerized transcription factor complexes (Chen et al., 2007).
It is present in the cytoplasm as an inactive dimer with the
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EXPERIMENTAL PROCEDURES
Bioinformatics Resources
Ligand Preparation
About 580 FDA-approved drugs were selected from
https://www.drugbank.ca/. The mol and SDF files were saved
from online databases such as Chemspider1 and PubChem2 .
The files were then changed to PDB format with the help of
the Biovia Discovery Studio software (DSV). We used the
Auto-Dock program to investigate ligand–protein affinity.
Affinity was determined by the ligand-receptor complex’s
E-value or the binding power value (Kcal/mol) of the best
pose. Ligands were docked against the single target NFκB. The 3D-structure of target protein was obtained from
http:/www.rcsb.org/pdb/home/home.do in PDB format
with PDB ID: ILE5/ILE9, which was then purified using
Discovery Studio Visualizer. Discovery Studio Visualizer was
also utilized for post-docking analysis and a creating a schematic
representation of hydrogen bonds, hydrophobic interactions,
and amino acid residues involved in ligand–protein complexes
(Shah et al., 2018; Al Kury et al., 2019).
Active Site Identification of NF-κB
The crystal structure of NF-κB (PDB ID: ILE9/ILE5) was
retrieved online from (http://www.rcsb.org). The NF-κB active
1 http://www.chemspider.com/
2 https://pubchem.ncbi.nlm.nih.gov/
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were administered intraperitoneally 30 min after occlusion and
before reperfusion, and then daily for 3 days. Rats were sacrificed
6 h after the last dose, and brain tissue was extracted and stored at
−80◦ C. Twenty rats died during surgical procedures, including
five from the MCAO group, five from Atorvastatin + MCAO,
four from Cephalexin + MCAO, three from Mycophenolate +
MCAO, and three from CAPE + MCAO, which we further
adjusted by adding more rats (Figure 1).

site (tyrosine 36, arginine-54, arginine-56, tyrosine-57, cysteine59, glutamic acid-60, histidine-64, lysine-144, lysine-145, lysine272, glutamine-274, and arginine-305) was determined through
a literature survey (Chen et al., 1998; Berkowitz et al., 2002). The
structure of NF-κB was then purified using DSV.

Docking Studies
In the present study, about 580 approved drugs were docked
for their potential role in stroke using NF-κB as a target by
the in-silico approach. Each drug was virtually docked against
NF-κB through an AutoDock Vina 4.2 (Trott and Olson,
2010) suit of PyRx to achieve an optimal complementarity
of steric and physicochemical properties. The number of
runs for each docking was set to 100. It has a grid map
to aid the actual docking process with exhaustiveness of
eight. To attain the best compounds using the comparative
docking approach, these drugs were also used for docking
through PatchDock. Afterward, hydrophobic and electrostatic
interactions were mapped using Discovery Studio Visualizer
(Meng et al., 2006). Three drugs—atorvastatin, cephalexin,
and mycophenolate—were selected for in vivo analysis and
biochemical studies.

Middle Cerebral Artery Occlusion (MCAO) Surgery
MCAO was performed as previously described (Shah et al.,
2014, 2016, 2018, 2019a). Briefly, rats were anesthetized with
ketamine and xylazine (3.2:1, I/P) mixture. The right common
carotid artery (CCA) and external carotid artery (ECA) were
dissected through a midline cervical incision without damaging
the vagus nerve, and a temporary suture as well as a permanent
suture were made around CCA and ECA, respectively, using
(6/0) silk. A microvessel clip was placed around the internal
carotid artery (ICA) and the pterygopalatine artery (PPA). A
small incision was made in the ECA, and a nylon filament
(3/0) about 30 mm with a blunted rounded tip was inserted
(Figure 1). The filament was guided from the ECA into the
ICA and progressed more into the origin of the middle cerebral
artery until the resistance was felt. The filament was remained
in place for 90 min and gently pulled back after due time
to recanalize the vessel, and the suture was made around
the ECA open end. The incision was closed by continuous
surgical suture. The sham group was exposed to the same
experimental procedure except for filament insertion. After 72 h
of reperfusion, the animals were decapitated, and brain samples
were collected.

Chemicals and Reagents
PBS tablets and proteinase K were obtained from (MP Bio USA).
Formaldehyde, hydrogen peroxide (H2O2), reduced glutathione
(GSH), trichloroacetic acid (TCA), 1-chlor-2,4-dinitrobenzene
(CDNP), N-(1-Naphthyl) ethylenediamine dihydrochloride,
5,50 -dithio-bis-(2- nitro benzoic acid; DTNB), and caffeic
acid phenethyl ester (CAPE) were purchased from (SigmaAldrich, USA). Atorvastatin, cephalexin, and mycophenolate
were obtained from the local pharmaceutical industry with
the highest analytical grade (99% HPLC grade). Mouse
monoclonal anti-TNF-α (SC-52B83), mouse monoclonal antip-NF-κB (SC-271908), mouse monoclonal anti-COX-2 (SC514489), mouse monoclonal anti-GFAP (SC-33673), ABC Elite
kit (SC-2018), and 3,30 -diaminobenzidine peroxidase (DAB; SC216567) were purchased from (Santa Cruz Biotechnology, USA).
The horseradish peroxidase-conjugated secondary antibody (ab6789) and mounting media (ab-10431) were obtained from
Abcam UK. The p-NF-κB Elisa kit (Cat # SU-B28069) and pJNK (Cat # SU-B30586) Elisa kit were purchased from (Shanghai
Yuchun Biotechnology, China).

Neurobehavioral Testing
To evaluate the sensorimotor functions of the rats undergoing
MCAO, a 28-point composite neuro score was used. This neuro
score consisted of 11 tests with a cumulative maximum score
of 28 (Shah et al., 2019b). These tests included: (1) circling
(maximum four points); (2) motility (maximum three points);
(3) general condition (maximum three points); (4) righting
reflex (maximum one point); (5) paw placement (maximum
four points); (6) horizontal bar (maximum three points);
(7) inclined platform (maximum three points); (8) grip
strength (maximum two points); (9) contralateral reflex
(maximum one point); (10) contralateral rotation when held
by the base of tail (maximum two points); and (11) visual
forepaw reaching (maximum two points). A 0-score indicated
severe neurological impairment, while a cumulative score of
28 indicated healthy functioning.

Animals and Drug Treatment
Sprague Dawley (SD) male rats (220–300 g) were kept
under circadian lighting conditions, and food and water were
allowed ad libitum. During this period, the bodyweight of
each animal was measured on alternative days. All the study
protocols were approved by the research and ethical committee
(REC/RIPS/2018/09) of Riphah Institute of Pharmaceutical
Sciences, Riphah International University, Islamabad. The rats
were arbitrarily divided into six experimental groups (n = 10):
Sham-treated group; diseased group/MCAO group: atorvastatin
(20 mg/kg) treated group/Atorvastatin + MCAO; cephalexin
(15 mg/kg)-treated group/Cephalexin + MCAO; mycophenolate
(200 mg/kg)-treated group/Mycophenolate + MCAO; and the
CAPE (10 mg/kg)-treated group/CAPE + MCAO. These drugs
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TTC (2,3,4-triphenyltretrazolium Chloride) Staining
At the end of the 72-h period, rats were executed under
anesthesia. The brain tissues were carefully removed and
washed with phosphate buffer solution (PBS). The brain tissues
were stored at −80◦ C for few minutes. Thick coronary slices
(2 mm) were made using the sharp blade from the frontal lobe
and then incubated in 2% 2,3,4-triphenyl tetrazolium chloride
(TTC) solution for 20–30 min until a full demarcation was
observed for MCAO-operated rats, while deep red staining
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FIGURE 1 | Schematic presentation of experiment: rats acclimatization, middle cerebral artery occlusion (MCAO) surgery, drug administration, neurobehavioral
studies, euthanization of rats for tissue collection to carry out biochemical analysis, i.e., glutathione-S-transferase (GST), glutathione (GSH), catalase and lipid
peroxidation (LPO), morphological analysis (2,3,4-triphenyl tetrazolium chloride staining, hematoxylin and eosin staining, and immunohistochemistry), and
biochemical assay (enzyme-linked immunosorbent assay ELISA). The red arrow indicates the blue nylon silk (3/0) approximately 3 cm in length with a bulging tip.

was used for sham-operated rats (Park et al., 2018). Later, a
4% paraformaldehyde solution was used to fix these coronal
slices, and they were kept at 4◦ C until utilized. The slices were
then photographed for % infarct area using ImageJ software.
Moreover, the corrected brain infarction was measured as follow:
Corrected infarct area = left hemisphere area − (right
hemisphere area − infarct area)/total area.
These coronal slices were then embedded in paraffin wax, and
thin 4 µm coronal sections were made by rotary microtome for
further morphological analysis.

Immunohistochemical Staining and Analysis
Immunohistochemical staining and analysis were done as
described previously with little modifications (Sung et al.,
2012; Ali et al., 2018). Slides were first de-paraffinized
with absolute xylene (100%) followed by rehydration with
absolute ethanol in gradient series starting from 100% to
70%. The slides were then treated with proteinase K, an
enzymatic process of antigen retrieval, and then washed with
0.1 M PBS. To block the peroxidase activity, 3% hydrogen
peroxide (H2 O2 ) diluted in methanol was used. Later on,
slides were washed with PBS and then incubated with
normal goat serum (3%–5%) that contained 0.1% Triton
X-100. Overnight incubation was performed with primary
antibodies, such as TNF-α, p-NF-κB, COX-2, and GFAP
(Dilution 1: 100, Santa Cruz Biotechnology, USA). The
following day, 0.1 M PBS was used twice for washing the
slides and incubated for 90 min with secondary antibody
[biotinylated secondary antibody (dilution factor 1:50)] and
then with ABC Elite kit (Santa Cruz Biotechnology, USA) in
a humidified chamber for 1 h. Then slides were stained in
DAB solution after rinsing with 0.1M PBS, and dehydration
was done with graded ethanol series. The slides were covered
with mounting media after fixing with xylene. A light
microscope (Olympus, Japan) was used for capturing the
immunohistochemical TIFF images. p-NF-κB, TNF-α, COX-2,
and GFAP were quantitatively analyzed by ImageJ software.
The intensity is expressed as the relative integrated density to
the sham.

Hematoxylin Eosin (H&E) Staining
First, slides were de-paraffinized with absolute xylene (100%),
rehydrated with absolute ethanol in gradient concentrations
starting from 100% to 70%, and lastly washed with distilled water.
Then, slides were dipped in hematoxylin for 10 min, before they
were retained in a glass jar under running water for 5 min.
These slides were dipped in ammonia water (1%) and HCl (1%)
for a short interval and immediately rinsed with water (Khan
et al., 2019). Slides were then immersed into eosin solution for
5–10 min, rinsed with water, and air-dried. Graded ethanol (70%,
95%, and 100%) was used to dehydrate the dried slides and
then mounted with coverslips. An Olympus light microscope
(Olympus, Japan) was used for capturing pictures and ImageJ
was used for the analysis of pictures. A total of five images
were captured and analyzed per group while focusing specifically
on neuronal cells morphological integrity, such as size, shape,
infiltrated cells, and vacuolation (Ouh et al., 2014).
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Enzyme-Linked Immunosorbent Assay (ELISA)
p-NF-κB and p-JNK expression were measured using rat p-NFκB and rat p-JNK ELISA kits according to the manufacturer’s
instructions (Shanghai Yuchun Biotechnology, China). The
supernatants of brain tissue homogenates were treated with
designated antibodies in 96-well plates to quantify p-JNK
and p-NF-κB. The concentration of p-JNK and p-NF-κB was
determined by using ELISA microplate reader (BioTekELx808USA) after the reaction between enzyme and substrate. Values
were expressed as pictograms of cytokines per milliliter (pg/ml).
All the procedures were repeated at least three times.

interactions with the crucial residues of NF-κB (Supplementary
Figure). Twenty drugs were then scrutinized, namely,
methyldopa, metyrapone, aminocaproic acid, aminolevulinic
acid, atorvastatin, butalbital, caprylic acid, carbamoylcholine,
cephalexin, cytarabine, diazolidinyl urea, dolasetron, famciclovir,
fenoprofen, flucytosine, hydroxychloroquine, isradipine,
lenvatinib, L-carnitine, and mycophenolate, as shown in Table 1,
and the list was further reduced to atorvastatin, cephalexin,
and mycophenolate (Figure 2A, Table 2). The structures of
atorvastatin, cephalexin, mycophenolate, and CAPE were

Determination of the Lipid Peroxidation (LPO) in Tissue
Lipid peroxidation (LPO) in the rat brain was determined
as demonstrated previously (Callaway et al., 1998).
Homogenization of Rat forebrain was done in 20 mM TrisHCl, pH 7.4 (10 ml) at 4◦ C using a polytron homogenizer. The
supernatant was collected after centrifugation of homogenate
at 1,000 g for 10 min at 4◦ C. Freshly prepared ferric or ferrous
ammonium sulfate was added to brain homogenate (40 µl)
to perform lipid peroxidation and incubated for 30 min at
37◦ C. Afterward, 75 µl of 2-thiobarbituric acid (TBA; 0.8%)
was added which was prepared by dissolving TBA (400 mg) in
water (50 ml). The absorbance was measured at 532 nm using a
plate reader.

TABLE 1 | E-value (Kcal/mol) and post-docking analysis (interactions) of
methyldopa, metyrapone, aminocaproic acid, aminolevulinic acid, atorvastatin,
butalbital, caprylic acid, carbamoylcholine, cephalexin, cytarabine, diazolidinyl
urea, dolasetron, famciclovir, fenoprofen, flucytosine, hydroxychloroquine,
isradipine, lenvatinib, L-carnitine, and mycophenolate with nuclear factor kappa
beta (NF-κB).
FDA approved drugs

Methyldopa
Metyrapone
Aminocaproic acid
Aminolevulinic acid

GST, GSH and Catalase Activity
The levels of reduced glutathione (GSH) were measured by
Moron et al. (1979). The activity of catalase was analyzed by the
procedure described by Sinha (1972). The activity of glutathioneS-transferase (GST) was described by the method of Surapaneni
and Jainu (2014).

Atorvastatin

Butalbital
Capyrilic acid
Carbamoylcholine

Statistical Analysis
ImageJ software (Image J 1.301) was used to analyze the data
morphologically. Means ± SEM was used to represent the data.
One-way ANOVA was used to analyze the TTC, neurobehavior
results, and oxidative stress, and this was followed by post hoc
Bonferroni Multiple Comparison tests using graph pad prism-5
software. For all other morphological analysis and protein
quantification by Elisa, a two-way analysis of variance (ANOVA)
was used. Significant difference values p < 0.05 were represented
by symbol * or # while **or ## represented p < 0.01 and ∗∗∗ or
### represented p < 0.001. A significant difference relative to
sham was represented by the symbol * while significant difference
relative to MCAO was represented by symbol #.

Cephalexin
Cytarabine
Diazolidinylurea

Dolasetron
Famciclovir
Fenoprofen
Flucytosine

RESULTS

Hydroxychloroquine

Docking Analysis

Isradipine

About 580 FDA drugs were screened by in silico approach for
possible NF-κB inhibition relative to the referenced CAPE,
used as a standard inhibitor. Each compound was virtually
docked against NF-κB through AutoDock Vina 4.2 suit
of PyRx to achieve an optimal complementarity of steric
and physicochemical properties. Based on the more precise
docking parameters, about 360 drugs were screened out from
a total of 580 drugs that were showing polar and non-polar

Frontiers in Molecular Neuroscience | www.frontiersin.org

Lenvatinib
L-carnitine
Mycophenolate

Hydrogen
bonding

Van Dar Vaal
forces

Energy values
Kcal/mol

TYR-57
GLU-60
TYR-57
HIS-64
GLU-60
HIS-64
GLU-60
HIS-64
TYR-57
GLU-60
HIS-64
TYR-57
HI S-64
GLU-60
HIS-64
TYR-57
GLU-60
HIS-64
GLU-60
HIS-64
TYR-57
HIS-64
TYR-57
HIS-64

HIS-64

−6.3

TYR-56
GLU-60
ARG-56
TYR-57
ARG-56
TYR-57
ARG-56

−7.1

GLU-60

−6.3

ARG-56
TYR-57
ARG-56

−4.3

ARG-56
TYR-57
GLU-60

−7.1

ARG-56
CYS-59
GLU-60
GLU-60

−6.1

ARG-56
HIS-64
GLU-60

−5.9

GLU-60

−4.9

ARG-56
GLU-60
TYR-56
GLU-60
ARG-56
TYR-57
ARG-56
TYR-57
ARG-56
GLU-60

−5.8

TYR-57
HIS-64
TYR-57
GLU-60
TYR-57
HIS-64
TYR-57
HI S-64
TYR-57
HIS-64
TYR-57
HIS-64
GLU-60
HIS-64
GLU-60
HIS-64
TYR-57
HIS-64

−4.5
−4.6
−4.8

−4.1

−6

−8.3

−6.4

−7.1
−7.7
−4.4
−7

Abbreviations: TYR, tyrosine; GLU, glutamic acid; HIS, histidine; ARG, arginine;
CYS, cysteine.
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FIGURE 2 | 3D structures of atorvastatin, cephalexin, mycophenolate, caeffic acid phenethyl ester (CAPE), and the nuclear factor kappa beta (NF-κB).
(A) Atorvastatin, cephalexin, mycophenolate, and (CAPE) were retrieved from https://www.drugbank.ca/ and converted to PDB format. (B) The crystal structure of
NF-κB (PDB ID: ILE9/ILE5) was retrieved from RCSB. NF-κB active pocket composed of (tyrosine 36, arginine-54, arginine-56, tyrosine-57, cysteine-59, glutamic
acid-60, histidine-64, lysine-144, lysine-145, lysine-272, glutamine-274, and arginine-305) is shown by a red square.

TABLE 2 | E-value (Kcal/mol) and post-docking analysis of best pose of
atorvastatin, cephalexin, mycophenolate, and CAPE with NF-κB.
FDA drugs

E-Value
Kcal/mol

H-Bonds

Bonding
residues

Atorvastatin

−4.8

4

TYR-57
GLU-60
PRO-62
HIS-64

Cephalexin

−7.1

6

GLU-60
GLY-61
PRO-62
HIS-64
GLY-65
ASN-136

Mycophenolate

−7.0

3

TYR-57
HIS-64
SER-110

Caeffic acid phenethyl ester

−6.0

2

TYR-57
HIS-64
SER-110

residues of mycophenolate, cephalexin, atorvastatin, and CAPE
after docking with NF-κB, while the best-docked poses of
mycophenolate, cephalexin, atorvastatin, and CAPE were shown
in Figure 3. A docking analysis showed that atorvastatin fitted
to NF-κB with a bond distance of 1.93–3.09 Å, and indicating
high polar contacts (Figures 3A,B). Furthermore, four hydrogen
bonds were formed between atorvastatin and NF-κB residues
(TYR-57, GLU-60, PRO-62, and HIS-64). In addition, Van
der Waal and electrostatic interactions were also observed
which further provided stability to the atorvastatin/NF-κB
binding complex. The docking results of mycophenolate and
NF-κB are shown in Figures 3D,E. Here, three hydrogen bonds
were observed with NF-κB residues (TYR-57, HIS-64, and
SER-110). Post-docking interactions for cephalexin are shown
in Figures 3G,H. Cephalexin fitted to NF-κB with a bond
distance of 2.09–3.24 Åand the corresponding polar and other
electrostatic interactions are shown. Also, the docking results of
CAPE are shown in Figures 3J,K.

Atorvastatin and mycophenolate respectively form four and three hydrogen bonds with
NF-κB. Abbreviations: TYR, tyrosine; GLU, glutamic acid; PRO, proline; HIS, histidine;
SER, serine; GLY, glycine; ASN, asparagine. Cephalexin forms six hydrogen bonds with
a minimum E value (-7.1).

Effect of Test Drugs on Brain Infarction
and Neurodegeneration
Sensorimotor functions before and after MCAO (24 h, 48 h,
and 72 h) surgery were assessed with a 28-point neuro score
method as described previously (Lenzlinger et al., 2004; Table 3,
Figure 4A). Severe neurological defect was observed in the
MCAO group relative to sham control (p < 0.001), as shown
by a lesser composite score (Figure 4A). This neuro score was
significantly improved by treatment with atorvastatin (p < 0.01),
cephalexin (p < 0.01), and mycophenolate (p < 0.01) compared
to the MCAO group. Interestingly, a significant increase in
the neurological cumulative score was found overtime on

database3 ,

retrieved from the drug bank
converted into PDB
format using DSV as shown in Figure 2A. The structure of
p-NF-κB (PDB ID: ILE5/ILE9) was downloaded from the
RCSB website4 and shown in Figure 2B, and the active pocket
of p-NF-κB (shown by a red square) was docked with these
ligands. Table 2 showed the binding energies and binding
3 https://www.drugbank.ca/
4 http://www.rcsb.org/
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FIGURE 3 | Docking results and best pose of atorvastatin, mycophenolate, cephalexin, and CAPE. The post-docking analysis was visualized by discovery studio
software (DSV) in both 2D and 3D poses. Interaction between atorvastatin and NF-κB is shown by the panels (A,B), mycophenolate and NF-κB by the panels (D,E),
cephalexin and NF-κB by the panels (G,H), and CAPE and NF-κB by the panels (J,K). 3D poses are shown by panels (A,D,G,J) and 2D by panels (B,E,H,K). Panels
(C,F,I,L) represent the best pose of atorvastatin, mycophenolate, cephalexin, and CAPE fitted to the active pocket of NF-κB. Abbreviations: TYR, tyrosine; GLU,
glutamic acid; PRO, proline; HIS, histidine; SER, serine; GLY, glycine; ASN, asparagine.

(p < 0.001), with the corrected infarcted area being reduced by
20.2 ± 3.76% (p < 0.05), 27.33 ± 3.8% (p < 0.05), 16.29 ± 6.54%
(p < 0.01), and 14.40 ± 5.6% (p < 0.01) for mycophenolate,
atorvastatin, cephalexin, and CAPE respectively. Cephalexin and
mycophenolate treated group showed a significant reduction
in corrected infarct area when compared with atorvastatin as
shown in Figure 4B.
H and E staining was used to determine the extent of
neuronal injury in cortex and striatum. We found aberrant
morphological features, variations in color staining, such as
cytoplasmic pyknosis and nuclear basophilia, distorted neuronal
size and shape, such as swelling and scalloped angular
neuronal cells, as well as inflammatory infiltrated cells in
the ipsilateral cortex and striatum (Figure 4C). Treatment
with atorvastatin, cephalexin, and mycophenolate significantly
attenuated this damage both in the cortex and striatal
tissue (p < 0.01), similarly to the CAPE-administered group
(p < 0.01; Figure 4C).

TABLE 3 | Twenty-eight-point composite neuro score.
Test

Test name

1
2
3
4
5
6
7
8
9
10
11

Circling
Motility
General condition
Righting reflex
Paw placement
Horizontal bar
Inclined platform
Grip strength
Contralateral reflex
Contralateral rotation
Visual forepaw reaching
Accumulative score

Score
4
3
3
1
4
3
3
2
1
2
2
28

days 2 and 3 after MCAO in rats treated with atorvastatin,
cephalexin, and mycophenolate, indicating that a spontaneous
sensorimotor functional recovery occurred after MCAO (data
not shown).
TTC staining was performed to examine the neuroprotective
effects of atorvastatin, cephalexin, and mycophenolate.
Considerable infarct changes were observed in MCAO
group (39.1 ± 4) as compared to sham-operated group
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FIGURE 4 | Effect of test drugs on brain infarction and neurodegeneration. (A) 28 points composite scoring. Data are presented as Mean ± SEM, analyzed by
one-way ANOVA (n = 10/group). ***Indicates p < 0.001, and ## represent p < 0.01. Symbols *shows significant difference relative to sham control while # shows
significant difference relative to the MCAO group. (B) Brain coronal sections were stained with TTC which distinguishes between ischemic and non-ischemic areas
(n = 5/group). ***Indicates p < 0.001, while symbol ## represent p < 0.01 significant difference and # indicates p < 0.05. The symbol *shows significant difference
relative to sham control while # shows significant difference relative to MCAO. The parietal cortex, striatum, hippocampus and thalamus region are respectively
shown by green, blue, black, and yellow arrows. (C) Representative photomicrographs of hematoxylin and eosin staining, showing the extent of neuronal injury. Data
are presented as Mean ± SEM, analyzed by two-way analysis of variance (ANOVA). scale bar 50 µm, magnification 40X. Slides were made from TTC sections, fixed
(Continued)
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increased in atorvastatin-, cephalexin-, and mycophenolatetreated groups compared to that of MCAO. Atorvastatin +
MCAO group showed a marked increase in the levels of
GSH (60.35 ± 1.86 and 32.8 ± 1.65), GST (54.4 ± 1.59 and
25.315 ± 2.56), and catalase (23.15 ± 1.43 and 17.57 ± 1.53) in
the cortex and striatum, respectively (Tables 4 and 5).

FIGURE 4 | Continued
initially in 4% paraformaldehyde. From these sections, paraffin blocks were
made and later 4 µm thin coronal sections were prepared by a rotary
microtome (n = 5/group). The neuropil of the ipsilateral cortex is characterized
by intensive vacuolation, swelling and scalloped neurons with intense
cytoplasmic eosinophilia and nuclear basophilia along with pyknotic nuclei.
Treatment with test drug substances attenuated the extent of neuronal death
and more surviving neurons could be seen in the ipsilateral cortex and
striatum. ***Indicates p < 0.001, while ## represent p < 0.01 significant
difference; # indicates p < 0.05. The symbol * shows significant difference
relative to sham control while # shows significant difference relative to MCAO.

Effect of Test Drugs on the Expression of
p-NF-κB
To determine the possible effects of atorvastatin, cephalexin,
and mycophenolate on p-NF-κB levels, an ELISA was performed
in the cortex and striatum according to the manufacturer’s
guidelines (Shanghai Yuchun Biotechnology, China). As shown
in Figure 5A, all three drugs showed statistically significant
decreased when compared with the MCAO group in both the
cortex and striatum (p < 0.05 atorvastatin, p < 0.05 cephalexin,
and p < 0.05 mycophenolate in the cortex and in the
striatum. CAPE (10 mg/kg) treatment also attenuated pNF-κB expression in the cortex (p < 0.01) and striatum
(p < 0.05), as shown in Figure 5A. These results were
further validated by immunohistochemical analysis (Figure 5B).
Together, these results suggested that atorvastatin, cephalexin,
and mycophenolate could modulate NF-κB phosphorylation
levels, and this accounts for its neuroprotective effects.

important indicator of oxidative stress and can be measured by
thiobarbituric acid reactive substances (TBARS). A TBARS test
was performed, and peroxides showed a drastic increase in the
MCAO group, an effect that could be rescued by atorvastatin,
cephalexin, and mycophenolate treatment. The LPO content
in the cortex of the MCAO group was (45.9 ± 1.79) as
compared to the sham group (25.9 ± 0.28; p < 0.001, Table 4).
Atorvastatin, cephalexin, and mycophenolate attenuated this
increased contents of TBRAS with 20.1 ± 1.28 (p < 0.01),
19.4 ± 1.49 (p < 0.01), and 18.85 ± 1.26 (p < 0.01), and the
effects that could match to that of CAPE group 18.85 ± 1.26
(p < 0.01) in the cortex. Similarly, peroxide levels were decreased
in the striatum of rats treated with atorvastatin (18.8 ± 1,
p < 0.01), cephalexin (17.15 ± 1, p < 0.01), and mycophenolate
(16.45 ± 1.04, p < 0.01) compared to the MCAO group
(35.53 ± 1.71) as shown in Table 5. Furthermore, the antioxidant
effect of atorvastatin, cephalexin, and mycophenolate were
examined using GST, GSH, and catalase levels both in cortex
and striatum (Tables 4, 5). Non-enzymatic antioxidant GSH
and enzymatic antioxidant catalase and GST were significantly

Effect of Test Drugs on the Inflammatory
Cascade
NF-κB is comprised of p65 (RelA), RelB, c-Rel, p105/p50
(NF-κB1), and p100/p52 (NF-κB2; Oeckinghaus and Ghosh,
2009). The inactive complex of NF-κB is bound by an
inhibitory subunit of κB inhibitors (IκB), which is present in

TABLE 4 | Effect of atorvastatin, mycophenolate, cephalexin, and CAPE on oxidative enzymes in the cortex.
Groups

Sham
MCAO
Atorvastatin + MCAO
Cephalexin + MCAO
Mycophenolate + MCAO
CAPE + MCAO

GST (µM CDNB conjugate/
min/mg of protein)

GSH (µM/mg of protein)

Catalase (µM H2 O2 /
min/mg of protein)

62.7 ± 1.98
25 ± 1.72***
54.4 ± 1.59##
49.4 ± 1.57#
44.65 ± 0.44#
60.25 ± 1.02##

65.55 ± 1.59
20.65 ± 1.58***
60.35 ± 1.86##
52.25 ± 1.39#
48.1 ± 1.41#
63.2 ± 1.34##

38.25 ± 1.76
18.65 ± 2.31***
23.15 ± 1.43#
19.1 ± 1.56#
18.05 ± 1.62#
34.25 ± 1.30##

L-PO nmol/MDA/
mg of protein
25.9 ± 0.28
45.9 ± 1.79***
20.1 ± 1.28##
19.4 ± 1.49##
18.85 ± 1.26##
18.85 ± 1.26##

Data were presented as Mean ± SEM, n = 5/group. Data were analyzed by one way ANOVA followed by post-hoc Bonferroni Multiple Comparison test using graph-pad prism-5
software. ***p < 0.001 shows a significant difference compared to sham, while ## or # show respectively p < 0.01 or p < 0.05 relative to MCAO. After euthanasia, brain tissue samples
were collected and preserved at -80◦ C. Abbreviations: GST, glutathione S-transferase; GSH, glutathione; LPO, lipid peroxidase.

TABLE 5 | Effect of atorvastatin, mycophenolate, cephalexin, and CAPE on oxidative enzymes in the striatum.
Groups

Sham
MCAO
Atorvastatin + MCAO
Cephalexin + MCAO
Mycophenolate + MCAO
CAPE + MCAO

GST (µM CDNB conjugate/
min/mg of protein)

GSH (µM/mg of protein)

Catalase (µM H2 O2 /
min/mg of protein)

41.95 ± 0.77
8.2 ± 2.12***
25.315 ± 2.56#
22.95 ± 1.34#
15.835 ± 1.74
28.28 ± 1.81##

63.9 ± 1.77
12.85 ± 1.64***
32.8 ± 1.65#
14.16 ± 1.28
11.55 ± 1.76
42.25 ± 1.40##

21.6 ± 1.37
7.11 ± 0.56***
17.57 ± 1.53##
16.47 ± 1.79##
12.35 ± 1.72#
19.92 ± 1.90##

L-PO nmol/MDA/
mg of protein
12.15 ± 1.61
35.53 ± 1.71***
18.8 ± 1.0##
17.15 ± 1.07##
16.45 ± 1.04##
20.85 ± 1.09##

Data were presented as means ± standard error of the mean (SEM). Data were analyzed by one way ANOVA followed by posthoc Bonferroni Multiple Comparison test using graph-pad
prism-5 software. ***p < 0.001 shows a significant difference compared to sham, while ## or # show respectively p < 0.01 or p < 0.05 relative to MCAO. After euthanasia, brain tissue
samples were collected and preserved at -80◦ C. Abbreviations: GST, glutathione S-transferase; GSH, glutathione; LPO, lipid peroxidase.
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FIGURE 5 | Effect of test drugs on p-NF-κB. Panel (A) illustrates the effect of atorvastatin, cephalexin, mycophenolate, and CAPE on p-NF-κB expression in cortex
and striatum by Elisa. Two-way analysis of variance (ANOVA) was used to analyze the results. The expression level of p-NF-κB was significantly decreased in the
treatment vs. MCAO group. ** indicates p < 0.01, while ## represent p < 0.01 significant difference, and # indicates p < 0.05. Symbols * shows significant
difference relative to sham control while # shows significant difference relative to MCAO. (B) Effect of atorvastatin, cephalexin, mycophenolate, and CAPE on
immunohistochemistry of p-NF-κB in cortex and striatum. Two-way ANOVA was used to analyze the data, scale bar 20 µm, magnification 40X and (n = 6/group).
p-NF-κB exhibits nuclear localization, *** indicates p < 0.001, while symbol ** represent p < 0.01, and # indicates p < 0.05 significant difference. The symbol *
shows significant difference relative to sham control while # shows significant difference relative to MCAO.

as a prominent controller of a variety of pathological or cell
death cascades (Russo et al., 2002; Li et al., 2017). In numerous
animal models of acute ischemic injury, NF-κB inhibition has
been proved to be protective (Manna et al., 2000; Wang et al.,
2010). In this regard, we performed a comparative analysis
of three FDA-approved drugs—atorvastatin, cephalexin, and
mycophenolate—in ischemic brain injury, to evaluate their
possible neuroprotective role based on drug repurposing.
The bioinformatics analysis was further supported with
experiments in MCAO models, where all three drugs showed
anti-inflammatory and neuroprotective properties.
In silico studies are a fast and cost-effective technique for
new drug development (Prakhov et al., 2010). Auto-Dock
vina, patch dock, gromacs, and gold suite are widely used for
ligand docking, while lower binding values (kcal/mol) reveal
reduced energy of desolvation, which depicts the stability of
ligand–protein complexes (Pecsi et al., 2010). It is necessary
to mention that binding energy is a cumulative result of
hydrogen bonds, covalent bonds, hydrophobic interactions,
and weak interactions, like van der Waals forces, between
a ligand and receptor. Steric bumps in a ligand–receptor
complex are responsible for instability, while hydrogen bonds
play a significant role in the stability of a complex and
strong affinity (Zhao and Huang, 2011). A comparative study
was conducted to compare the results of the test ligands
to that of standard drug, which was obtained from RCSB
and PubChem. In our study, test compounds atorvastatin,

the cytoplasm. Pro-inflammatory cytokines, including tumor
necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β),
bind to their corresponding receptors that further link to
downstream molecules, thus involving the sequential activation
of ASK1, SEK1, and p-JNK. These lead to IκB phosphorylation
and proteasomal degradation, result in NF-κB release and
nuclear translocation, and subsequently induce the transcription
of inflammatory proteins such as inducible nitric oxide (i-NOS)
and cyclo-oxygenase (COX-2; Yao et al., 2013).
Moreover, this inflammatory pathway was further examined
with an ELISA assay for p-JNK (Figure 6A), which showed
higher expression in the MCAO group, whereas the level of pJNK was significantly ameliorated in the drug treatment groups
(p < 0.05 cephalexin, p < 0.05 mycophenolate in the cortex as
well as p < 0.05 mycophenolate, p < 0.001 atorvastatin, and
p < 0.01 cephalexin in the striatum). Immunohistochemistry
was performed to further validate the ELISA results, which
showed elevated expression of GFAP, COX-2, TNF-α in cortex
and striatum after ischemic injury (Figures 6B–D). Atorvastatin,
cephalexin, and mycophenolate significantly decreased the
expression of COX-2, TNF-α, and GFAP.

DISCUSSION
Ischemic brain injury involves the disturbance of stable networks
involving multiple signaling pathways and a variety of genes
(Sung et al., 2016). Among them, NF-κB has been considered
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FIGURE 6 | Effect of test drugs on the inflammatory cascade. Effect of atorvastatin, cephalexin, mycophenolate, and CAPE on inflammatory markers. (A) Elisa
analysis of p-JNK. The data are expressed as the Mean ± SEM. ***p < 0.001 relative to sham while ## or # show respectively p < 0.01 or p < 0.05 relative to MCAO,
with n = 5/group, After euthanasia, brain tissues were collected and preserved at -80◦ C and later processed for protein analysis. The p-JNK was significantly
expressed in the MCAO group relative to sham, while treatment with test drugs attenuated the MCAO induced hyperexpression of JNK in cortex and striatum. (B)
Immunohistochemistry results for astrocytes (GFAP) in the cortex and striatum tissues of the brain (C) Immunohistochemistry of COX2 in the cortex and striatum
tissues of the brain and (D) Immunohistochemistry of TNF-α in the cortex and striatum tissues of the brain. Immunoslides were processed from stained TTC coronal
sections. From the thick coronal TTC sections, paraffin blocks were made and later 4 µm thin coronal sections were prepared by a rotary microtome.
(Continued)
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is well established (Behn et al., 2007). Therefore, a therapeutic
strategy having an antioxidant effect may be considered an
effective approach. Treatment with mycophenolate at 200 mg/kg
dose reduced the oxidative stress, and this was similar to
previous findings. Likely, we observed that different oxidative
damage parameters are the critical determinants in I/R brain
injury, which causes a significant increase in LPO and protein
oxidation accompanied by significant depletion in brain GSH as
well as a decrease in GST and catalase. Therefore, scavenging
free radicals and preventing lipid and protein peroxidation by
CAPE and tested drugs can suppress oxidative damage and
inflammatory responses. GSH, GST, and catalase levels were
reduced in the MCAO group, which may render the susceptibility
of plasma membranes towards peroxide and other free radicals’
attacks. Accordingly, we observed an elevated level of TBARS,
accompanied by depleted GSH, GST, and catalase level in MCAO
where post-treatment with CAPE and test drugs reversed these
effects, is concomitant with the previous observations where
antioxidants were used as a remedy in experimental stroke
models (Meng et al., 2006; Khan et al., 2009; Wang et al., 2010).
The observed neuroprotective effect of mycophenolate could be
partially attributed to its anti-oxidant activity, as mycophenolate
treatment at doses of 100 and 200 mg/kg ameliorated the raised
NO activity after 24 h of ischemia (Bilginer et al., 2009).
Our results demonstrated that cephalexin, mycophenolate,
and atorvastatin reduced the expression of proinflammatory
cytokines and oxidative stress-related factors like TNF-α, GFAP,
and COX-2. Moreover, our results also indicated that cephalexin
can be a strong scavenger of ROS and a potent inhibitor of NF-κB
derived inflammation, which may deserve further exploration as
of its future application. Our results provided the first targeting

FIGURE 6 | Continued
Scale Bar 50 µm, magnification 40X, (n = 5/group). GFAP exhibits a
characteristic morphological shape, while COX2 and TNF-α exhibited
cytoplasmic localization. ***p < 0.001 shows a significant difference
compared to sham, while ## or # show respectively p < 0.01 or p < 0.05
relative to MCAO. Data are presented as Mean ± SEM and analyzed by
GraphPad Prism 8 software.

cephalexin, and mycophenolate showed a high affinity to the
NF-κB receptor as compared to a standard drug, i.e., CAPE.
Our study found cephalexin and mycophenolate manifested
the best binding score with the lowest E-value against NF-κB.
Based on the E-value, the order of ligand affinity was found as
cephalexin > mycophenolate > CAPE > atorvastatin. Previous
studies demonstrated that atorvastatin markedly reduced brain
edema and infarct size at 24 h of ischemic injury and
significantly suppressed the upregulation of NF-κB (Cheng et al.,
2018). Atorvastatin may also prevent an NF-κB shift from the
cytoplasm to the nucleus, which could be attributed to the
downregulation of HMGB1 (Wang et al., 2010). Also, previous
studies with statin showed a decrease in infarct volume by
both pretreatment and posttreatment (Baryan et al., 2012).
In another study, simvastatin significantly reduced the infarct
volume size (38.18%), as compared to atorvastatin (23.71%)
and rosuvastatin (13.88%; Garcia-Bonilla et al., 2014). Similarly,
previous studies showed that post MCAO treatment with
mycophenolate (200 mg/kg) for three successive days resulted
in a significant reduction in infarct volume size. In agreement
with these results, our study demonstrated that atorvastatin
reduced the infarct volume, decreased p-NF-κB expression in
the cortex and striatum.The role of oxidative stress in I/R injury

FIGURE 7 | Schematic diagram depicting pathological events following MCAO that mediate post-ischemic inflammation. NF-κB activation regulates the
inflammatory cytokines and adhesion molecules, and this leads to peripheral inflammatory cells migrating to the ischemic area and enhance ischemic brain injury.
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and mechanistic explanation for the neuroprotective effects
of cephalexin.
In conclusion, we demonstrated that cephalexin,
mycophenolate, and atorvastatin were identified as NF-κB
inhibitors as referred by CAPE with molecular docking.
Further experiments showed that treatment with cephalexin,
mycophenolate, atorvastatin, and CAPE reduced infarct area
and improved motor deficits. Furthermore, CAPE inhibited
NF-κB activation and thus preventing the expression of NF-κB
dependent genes including cytokines i.e., p-JNK, TNF-α and
COX2 as depicted by Figure 7.
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